China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection produ… Read more
Market Cap & Net Worth: China Resources Boya Bio pharmaceutical Group Co Ltd (300294)
China Resources Boya Bio pharmaceutical Group Co Ltd (SHE:300294) has a market capitalization of $1.42 Billion (CN¥10.45 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #8388 globally and #1580 in its home market, demonstrating a -0.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Resources Boya Bio pharmaceutical Group Co Ltd's stock price CN¥20.72 by its total outstanding shares 504248738 (504.25 Million).
China Resources Boya Bio pharmaceutical Group Co Ltd Market Cap History: 2015 to 2026
China Resources Boya Bio pharmaceutical Group Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.70 Billion to $1.42 Billion (-1.58% CAGR).
Index Memberships
China Resources Boya Bio pharmaceutical Group Co Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ChiNext
CNT
|
$625.44 Billion | 0.12% | #90 of 100 |
Weight: China Resources Boya Bio pharmaceutical Group Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
China Resources Boya Bio pharmaceutical Group Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Resources Boya Bio pharmaceutical Group Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.20x
China Resources Boya Bio pharmaceutical Group Co Ltd's market cap is 1.20 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
5.24x
China Resources Boya Bio pharmaceutical Group Co Ltd's market cap is 5.24 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.70 Billion | $543.18 Million | $151.80 Million | 3.14x | 11.22x |
| 2016 | $2.47 Billion | $946.60 Million | $272.04 Million | 2.61x | 9.10x |
| 2017 | $1.98 Billion | $1.39 Billion | $356.59 Million | 1.42x | 5.54x |
| 2018 | $1.79 Billion | $2.39 Billion | $469.17 Million | 0.75x | 3.81x |
| 2019 | $2.08 Billion | $2.91 Billion | $426.15 Million | 0.72x | 4.89x |
| 2020 | $2.24 Billion | $2.51 Billion | $260.06 Million | 0.89x | 8.63x |
| 2021 | $2.57 Billion | $2.65 Billion | $344.53 Million | 0.97x | 7.46x |
| 2022 | $2.46 Billion | $2.76 Billion | $432.20 Million | 0.89x | 5.70x |
| 2023 | $2.28 Billion | $2.65 Billion | $237.47 Million | 0.86x | 9.61x |
| 2024 | $2.08 Billion | $1.73 Billion | $396.99 Million | 1.20x | 5.24x |
Competitor Companies of 300294 by Market Capitalization
Companies near China Resources Boya Bio pharmaceutical Group Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to China Resources Boya Bio pharmaceutical Group Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
China Resources Boya Bio pharmaceutical Group Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, China Resources Boya Bio pharmaceutical Group Co Ltd's market cap moved from $1.70 Billion to $ 1.42 Billion, with a yearly change of -1.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.42 Billion | -8.32% |
| 2025 | CN¥1.55 Billion | -25.36% |
| 2024 | CN¥2.08 Billion | -8.79% |
| 2023 | CN¥2.28 Billion | -7.39% |
| 2022 | CN¥2.46 Billion | -4.17% |
| 2021 | CN¥2.57 Billion | +14.53% |
| 2020 | CN¥2.24 Billion | +7.83% |
| 2019 | CN¥2.08 Billion | +16.37% |
| 2018 | CN¥1.79 Billion | -9.47% |
| 2017 | CN¥1.98 Billion | -20.14% |
| 2016 | CN¥2.47 Billion | +45.29% |
| 2015 | CN¥1.70 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of China Resources Boya Bio pharmaceutical Group Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.42 Billion USD |
| MoneyControl | $1.42 Billion USD |
| MarketWatch | $1.42 Billion USD |
| marketcap.company | $1.42 Billion USD |
| Reuters | $1.42 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.